AbbVie Inc (ABBV)vsagilon health Inc (AGL)
ABBV
AbbVie Inc
$285.42
+0.71%
HEALTHCARE · Cap: $471.27B
AGL
agilon health Inc
$85.12
-3.76%
HEALTHCARE · Cap: $1.43B
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 988% more annual revenue ($64.39B vs $5.92B). ABBV leads profitability with a 9.8% profit margin vs -3.9%. ABBV earns a higher WallStSmart Score of 73/100 (B).
ABBV
Strong Buy73
out of 100
Grade: B
AGL
Hold41
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-84.3%
Fair Value
$152.52
Current Price
$285.42
$132.90 premium
Intrinsic value data unavailable for AGL.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 40.0%
Earnings expanding 290.4% YoY
Conservative balance sheet, low leverage
Growing faster than its price suggests
Earnings expanding 301.0% YoY
Conservative balance sheet, low leverage
Areas to Watch
Premium valuation, high expectations priced in
Distress zone — elevated risk
Distress zone — elevated risk
Smaller company, higher risk/reward
Operating margin of 1.3%
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 10.2% demonstrates continued momentum. PEG of 0.54 suggests the stock is reasonably priced for its growth.
Bull Case : AGL
The strongest argument for AGL centers on EPS Growth, Debt/Equity.
Bear Case : ABBV
The primary concerns for ABBV are P/E Ratio, Altman Z-Score. A P/E of 75.1x leaves little room for execution misses.
Bear Case : AGL
The primary concerns for AGL are Altman Z-Score, Market Cap, Operating Margin.
Key Dynamics to Monitor
ABBV profiles as a value stock while AGL is a turnaround play — different risk/reward profiles.
AGL carries more volatility with a beta of 3.00 — expect wider price swings.
ABBV is growing revenue faster at 10.2% — sustainability is the question.
ABBV generates stronger free cash flow (3.1B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (73/100 vs 41/100) and 10.2% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
agilon health Inc
HEALTHCARE · MEDICAL CARE FACILITIES · USA
agilon health, inc. The company is headquartered in Long Beach, California.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?